ADRIATIC Study Shows Durvalumab Boosts Survival in Limited-Stage SCLC David Spigel, MD, discusses the findings from and methodology behind the ADRIATIC study of durvalumab as consolidation therapy for patients with limited-stage small cell lung cancer.

🚀 Big news from SCRI! Dr. David Spigel presented results: Durvalumab shows a 27% reduction in death risk & a 22.5-month median survival boost in our global trial! Watch the video below to learn more. #TargetedOncology #ClinicalTrials #SCRI
www.targetedonc.com/view/adriati...

Stephanie Graff: Excited to have another therapeutic option to treat advanced HR+ breast cancer - OncoDaily Stephanie Graff: Excited to have another therapeutic option to treat advanced HR+ breast cancer / Breast Cancer, cancer, Datopotumab deruxtecan, FDA, HR+

Excited to have another therapeutic option to treat advanced HR+ breast cancer - Stephanie Graff
@drsgraff.bsky.social
@fda.gov

oncodaily.com/insight/step...

#BreastCancer #Cancer #DatopotumabDeruxtecan #FDA #HRpositiveBreastCancer #OncoDaily #Oncology #Health #TargetedOncology #Medicine